IP Library Granted Patent US 7,501,552
Granted Patent B2
US 7,501,552 · App. 11/009,873 · Granted Mar 10, 2009

Transgenic non-human animals for producing chimeric antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,501,552
App. No.
11/009,873
Granted
Mar 10, 2009
Kind
B2
Abstract

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

Claims (8)

1. A method for obtaining a somatically mutated antibody that binds to a predetermined antigen, which method comprises:

(a) immunizing a transgenic mouse with a predetermined antigen, wherein the transgenic mouse has a genome comprising inactivated endogenous murine heavy chain variable gene regions, and further comprising an unrearranged human heavy chain immunoglobulin variable region operably linked to a mu constant region gene segment,

wherein the unrearranged human heavy chain variable region comprises multiple human V H gene segments, multiple human D gene segments, and multiple human J H gene segments, and wherein the mu constant region is selected from the group consisting of (i) a human S-mu sequence and a human or mouse mu coding sequence and (ii) a mouse S-mu sequence and a human or mouse mu coding sequence,

(b) removing B lymphocytes from the transgenic mouse,

(c) identifying mouse IgG isotype immunoglobulin molecules that bind to the predetermined antigen expressed by the B lymphocytes; and

(d) isolating the IgG isotype immunoglobulin molecules that bind to the predetermined antigen, whereby a somatically mutated antibody that binds to the predetermined antigen is obtained from the B lymphocytes of step (c).

2. The method of claim 1 , wherein the mouse IgG isotype immunoglobulin molecules are identified by screening cells derived from the B lymphocytes to determine which immunoglobulin isotype is expressed.

3. The method according to claim 1 , wherein the IgG isotype immunoglobulin molecules are identified by isolating the nucleic acid molecules encoding the IgG immunoglobulin molecules from the B lymphocytes and determining the sequence of the heavy chain constant region.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2007
From: MEDAREX, INC.
To: GENPHARM INTERNATIONAL
Reel/Frame 019768/0165 →